Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.55 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11656718 | 0.85 | HSD17B10 (0.60) | HSD17B10MEN1KMT2AMAPTRAB9A | |
| SCHEMBL7996823 | 0.82 | MAPT (0.64) | HSD17B10MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL9122336 | 0.81 | HSD17B10 (0.60) | HSD17B10MEN1KMT2APDK1PDK2 | |
| SCHEMBL28182819 | 0.81 | MEN1 (0.56) | HSD17B10MEN1KMT2APDK1PDK2 | |
| SCHEMBL9404930 | 0.80 | VCAM1 (0.54) | HSD17B10MEN1KMT2APDK1PDK2 | |
| Hydrochloric Acid SCHEMBL9594133 | 0.80 | HSD17B10 (0.58) | HSD17B10MEN1KMT2APDK1PDK2 | |
| SCHEMBL29036913 | 0.80 | HSD17B10 (0.58) | HSD17B10MEN1KMT2APDK1PDK2 | |
| SCHEMBL5201333 | 0.80 | CYP19A1 (0.56) | HSD17B10MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL30641927 | 0.80 | KMT2A (0.66) | MEN1KMT2APDK1PDK2PDK3 | |
| SCHEMBL38656198 | 0.80 | CYP19A1 (0.56) | HSD17B10MEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618968-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7291616-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2003-08-14 | — | — | US | disclosed |
| WO-2003037346-A1 | 6-PHENYL-N-PHENYL-(1,3,5) -TRIAZINE-2,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOPHPHOSPHATIDIC ACID ACYLTRANSFERASE BETA (LPAAT-BETA) INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| US-5084449-A | Bactericides and antiprotozoa agents | DR. KARL THOMAE GMBH (DE) | 1992-01-28 | — | — | US | disclosed |
| US-4992430-A | Anti-bacterial compositions comprising a substituted bis-(4-aminophenyl)-sulfone and a dihydro-folic acid reductase | DR. KARL THOMAE GMBH (DE) | 1991-02-12 | — | — | US | disclosed |
| US-4829058-A | INHIBITORS OF BACTERIA, MYCOBACTERIA AND PLASMODIA | DR. KARL THOMAE GMBH (DE) | 1989-05-09 | — | — | US | disclosed |
| EP-0165422-B1 | SUBSTITUTED BIS-(4-AMINOPHENYL)-SULPHONES, THEIR PREPARATION AND THEIR USE AS MEDICINES | Dr. Karl Thomae GmbH (DE) | 1988-03-09 | — | — | EP | disclosed |
| EP-0165422-A1 | Substituted bis-(4-aminophenyl)-sulphones, their preparation and their use as medicines | Dr. Karl Thomae GmbH (DE) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | HSD17B10 887/4885MEN1 3342/4885KMT2A 252/4885 |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | HSD17B10 797/4885MEN1 3480/4885KMT2A 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.